)
Kyverna Therapeutics (KYTX) investor relations material
Kyverna Therapeutics Study update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study design and patient population
KYSA-8 is a single-arm, multicenter, open-label, phase II trial in Stiff Person Syndrome (SPS) with 26 patients who discontinued immunotherapies before miv-cel dosing.
KYSA-6 is a phase II trial in generalized Myasthenia Gravis (gMG) with seven patients who failed prior immunotherapies and stopped them before miv-cel treatment.
Both studies focus on patients with severe disease and high unmet needs who failed prior therapies.
Over 100 patients have been treated with miv-cel across autoimmune indications, showing consistent safety and efficacy.
Efficacy results in SPS (KYSA-8)
At one year, 95% of SPS patients maintained clinically meaningful improvement in the timed 25-ft walk test, with 24 of 26 remaining off immunotherapies.
Median walk time reduced by 49% from baseline at one year, with over one-third achieving healthy adult walking speed.
Statistically significant improvements were sustained across all primary and secondary endpoints at one year.
67% of patients who previously needed walking aids walked unassisted at one year.
92% of patients remained free of immunomodulatory or immunosuppressant therapies for SPS at one year.
Efficacy results in gMG (KYSA-6)
All seven gMG patients showed rapid and robust improvements in MG-ADL and QMG scores, sustained for at least one year.
Mean MG-ADL improvement was 8.2 points at 52 weeks; QMG improved by 12.8 points at 52 weeks.
100% of patients achieved clinically meaningful responses in MG-ADL, QMG, and MGC; 57% sustained minimal symptom expression at last follow-up.
Nearly all patients remained off chronic immunotherapies, reducing treatment burden.
86% of gMG patients remained off immunosuppressants at last follow-up.
- Miv-cel offers durable remission and strong safety in SPS, with expansion into gMG and PMS planned.KYTX
Investor presentation - Miv-cel shows transformative results in SPS and gMG, with regulatory and commercial milestones ahead.KYTX
H.C. Wainwright 28th Annual Global Investment Conference - Transformative cell therapy shows strong efficacy and safety, targeting near-term approval and launch.KYTX
Morgan Stanley 24th Annual Global Healthcare Conference - Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027.KYTX
Wells Fargo 21st Annual Healthcare Conference - Miv-cel achieved durable, drug-free remission in SPS and gMG with strong safety and commercial outlook.KYTX
Corporate presentation - Q2 2026 net loss narrowed to $38.3M as miv-cel advanced with FDA RMAT and strong cash reserves.KYTX
Q2 2026 - KYV-101 demonstrates transformative efficacy in autoimmune diseases, with pivotal data expected in 2026.KYTX
Jefferies London Healthcare Conference 2025 - Strong clinical data and FDA alignment position for first CAR T launch in autoimmune diseases.KYTX
Jefferies Global Healthcare Conference 2026 - Miv-cel achieved robust efficacy and safety in SPS, supporting a 2026 FDA submission.KYTX
Study Result
Next Kyverna Therapeutics earnings date
Next Kyverna Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)